EUVIMEDEUVIMED entdecken
Crossref

Clinical Characterization and Molecular Profiling by Targeted Next‐Generation Sequencing in a Large Indian Cohort With 46,XY Differences in Sex Development

Vandana Jain iD, Sukanya Priyadarshini iD, Rajni Sharma iD, Anil Kumar, Shilpa Sharma iD, Palany Raghupathy iD, Ralf Werner iD, Olaf Hiort iD, Mohammed Faruq iD

Clinical Endocrinology · 2026-06 · 104 (6) · 612-627

DOI: 10.1111/cen.70122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 08.03.2026. Verfasst von Vandana Jain und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Disorder of Sex Development, 46,XY, Sexual Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Indian Council of Medical Research, Bundesministerium fÜr Bildung und Forschung, the Indian Council of Medical Research, New Delhi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

46,XY differences in sex development (DSD) comprise a heterogeneous group of conditions. Molecular diagnosis guides management by giving insights into the pathophysiology of sex development, reproduction, tumour formation and extragenital issues.

Methods

Children with 46,XY DSD from a tertiary hospital in India underwent comprehensive assessment and stepwise genetic testing. Targeted testing for SRD5A2 and AR was performed in cases with suspected 5α‐reductase type 2 (5αR2) deficiency/androgen insensitivity syndrome (AIS). For all other patients, and those without variants in SRD5A2 or AR on Sanger sequencing, NGS using a targeted 155‐gene panel was performed. Longitudinal clinical data was also collated.

Results

One hundred and forty‐seven children with 46,XY DSD with a median (interquartile range) age of 3.8 (1.4, 10.6) years were enrolled. Provisional clinical diagnoses were 5αR2 deficiency/AIS ( n = 83, 56.5%), gonadal dysgenesis ( n = 31, 21%), testosterone biosynthetic defect ( n = 11, 7.5%) and others ( n = 22, 15%) based on clinical, biochemical and radiological assessment. Sequential single gene testing for SRD5A2 and AR performed in 75 patients with a clinical diagnosis of 5αR2 deficiency/AIS identified pathogenic/likely pathogenic variants in 44 subjects. NGS in the remaining 103 children revealed pathogenic/likely pathogenic variants in 20 subjects across 12 genes, with NR5A1 being the most frequent (7/103). Four subjects had variants of uncertain significance (VUS) deemed possibly pathogenic due to good genotype‐phenotype correlation. Overall, 68/147 (46%) achieved a molecular diagnosis in this cohort.

Conclusion

Sanger sequencing followed by NGS could provide molecular diagnosis in 46% of this Indian cohort with 46,XY DSD . SRD5A2 , AR and NR5A1 were the most frequently implicated genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Nucleotide SequencingDisorder of Sex Development, 46,XYSexual DevelopmentHumansChild, PreschoolMaleChild3-Oxo-5-alpha-Steroid 4-DehydrogenaseIndiaFemaleInfantMembrane ProteinsReceptors, AndrogenCohort StudiesGenetic TestingAndrogen-Insensitivity Syndrome

Stichwörter der Autor:innen

DSDNGSNR5A1exome sequencinggonadal dysgenesistargeted paneltestosterone biosynthetic defect

Substanzen

3-Oxo-5-alpha-Steroid 4-DehydrogenaseSRD5A2 protein, humanMembrane ProteinsReceptors, Androgen

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India.
  • Division of Pediatric and Adolescent Endocrinology, Indira Gandhi Institute of Child Health, Bangalore, India.
  • Division of Pediatric Endocrinology and Diabetes, Department of Pediatric and Adolescent Medicine, University of Lübeck, Lübeck, Germany.
  • Council of Scientific and Industrial Research - Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India.

ORCID-Profile: Vandana Jain, Sukanya Priyadarshini, Rajni Sharma, Shilpa Sharma, Palany Raghupathy, Ralf Werner, Olaf Hiort, Mohammed Faruq

Förderung

  • Indian Council of Medical Research
  • Bundesministerium fÜr Bildung und Forschung
  • the Indian Council of Medical Research, New Delhi
  • German Ministry for Research and Education

Zitieren

APA

Jain, V., Priyadarshini, S., Sharma, R., Kumar, A., Sharma, S., Raghupathy, P., Ralf Werner, Hiort, O., & Faruq, M. (2026). Clinical Characterization and Molecular Profiling by Targeted Next‐Generation Sequencing in a Large Indian Cohort With 46,XY Differences in Sex Development. Clinical Endocrinology, 104(6), 612-627. https://doi.org/10.1111/cen.70122

Vancouver

Jain V, Priyadarshini S, Sharma R, Kumar A, Sharma S, Raghupathy P, et al. Clinical Characterization and Molecular Profiling by Targeted Next‐Generation Sequencing in a Large Indian Cohort With 46,XY Differences in Sex Development. Clinical Endocrinology. 2026;104(6):612-627. doi:10.1111/cen.70122

BibTeX
@article{Jain2026,
  author = {Jain, Vandana and Priyadarshini, Sukanya and Sharma, Rajni and Kumar, Anil and Sharma, Shilpa and Raghupathy, Palany and Ralf Werner and Hiort, Olaf and Faruq, Mohammed},
  title = {Clinical Characterization and Molecular Profiling by Targeted Next‐Generation Sequencing in a Large Indian Cohort With 46,XY Differences in Sex Development},
  journal = {Clinical Endocrinology},
  year = {2026},
  volume = {104},
  number = {6},
  pages = {612--627},
  doi = {10.1111/cen.70122}
}
Kostenlos starten →